Skip to main content

Table 3 Comparison between laboratory results at baseline and at the end of treatment among the studied patients

From: Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

 

At baseline

At the end of treatment

P value

Hemoglobin (gm/dl)

12.22 ± 1.6

11.25 ± 1.5

P < 0.001

WBCs × 103/ml

4.63 ± 1.5

4.63 ± 1.7

P = 1.0

Platelet count × 103/ml

92.5 (50.0–356)

105 (37.0–392)

P = 0.26

ALT/ULN (folds)

1.255 (0.22–5.35)

0.67 (0.2–2.0)

P < 0.001

AST/ULN (folds)

1.75 (0.4–5.85)

0.9 (0.25–7.0)

P < 0.001

Serum albumin (gm/dl)

2.85 ± 0.4

3.23 ± 0.5

P < 0.001

Serum bilirubin (mg/dl)

1.37 (0.3–3.2)

1.2 (0.2–3.4)

P = 0.019

I.N.R.

1.33 ± 0.24

1.38 ± 0.24

P = 0.16

Serum creatinine (mg/dl)

0.84 ± 0.2

0.89 ± 0.3

P = 0.08

AFP (IU/l)

10.8 (0.1–201)

5.8 (0.2–24)

P < 0.001

  1. All parameters described as mean ± SD except platelet count, ALT/ULN, AST/ULN, serum bilirubin, and AFP as median (min–max)